Search results
Results from the WOW.Com Content Network
The Monthly Index of Medical Specialities or MIMS is a pharmaceutical prescribing reference guide published in the United Kingdom since 1959 by Haymarket Media Group.MIMS is also published internationally by various organisations, including in Australia, New Zealand, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
MIMS Ireland is used by the Irish Medicines Board to convey information on drug safety, [2] [3] and is a "recommended text" in the premises requirements for pharmacies issued by the Pharmaceutical Society of Ireland (PSI). [4]
Forrest Mims was born in 1944 in Houston, Texas to Forrest M. Mims, Jr. (1923–1996) and Ollieve E. (Dunn) Mims (1924–1995). [10] He was the oldest of five children, two boys and three girls. Mims' father was an Air Force pilot and the family lived on military bases from Alaska to Florida but their home state was Texas.
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.
Piracetam is a drug that has efficacy in cognitive disorders, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia; sources differ on its usefulness for dementia. [3] [4] [5] Piracetam is sold as a medication in many European countries.
Fentanyl is a highly potent synthetic piperidine opioid primarily used as an analgesic.It is 30 to 50 times more potent than heroin and 100 times more potent than morphine; [11] its primary clinical utility is in pain management for cancer patients and those recovering from painful surgeries.
Discover the best free online games at AOL.com - Play board, card, casino, puzzle and many more online games while chatting with others in real-time.
In February 2014, the US FDA granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by Alitair Pharmaceuticals, in May 2013. [6] [7] [8]